I’m not a great fan of Twitter lists, especially those that imply you are a “Top Cat,” because they can end up being divisive and generate resentment in those not included.
That said, without wishing to offend anyone, here’s my initial starting point of those I will be following at the 2012 annual meeting of the American Society of Hematology in Atlanta from December 8 – 11 (#ASH12):
American Society of Hematology
- ASH @ASH_hematology
- ASCO Post @ASCOpost
- The Myeloma Beacon @myelomabeacon
- Pharma Strategy Blog / Sally Church, PhD @MaverickNY
- Leukemia & Lymphoma Society @llsusa
- Multiple Myeloma Research Foundation @theMMRF
- International Myeloma Foundation @IMFmyeloma
- Cynthia Chmielewski @MyelomaTeacher
Companies /Industry Execs
- Takeda/Millennium @Millennium_US
- Boehringer @Boehringer (added Dec 3)
- Infinity IR & Corp Comm (unofficial) @JarenM
Physicians/Researchers & Institutions
- James Berenson, MD @myelomadoc
- Sam Blackman, MD @drsam (added Dec 6)
- Duane Hassane, PhD @DrDuaneHassane
- Scott Merville @smerv (Communications Manager Basic/Translational Research, M.D. Anderson Cancer Center)(added Dec 6)
- Oleg Kolupaev @okolupaev
- Robert Z. Orlowski, MD @Myeloma_Doc
- Mike Thompson, MD @mtmdphd (will not be at ASH but worth following for commentary)
- Michael Tomasson, MD @mtomasson
- Anas Younes, MD @DrAnasYounes
This is not intended to be a definitive list, so I encourage you to watch the #ASH12 Twitter stream for additional people to follow depending on your interests. I have intentionally not included PR folks, investors, journalists who are usually too busy writing their own stuff and exhibitors who just want to tweet their own news. However, if I have missed anyone who has a burning desire to be included, please contact me.
Wifi permitting (always a big IF since many conference venues have not invested sufficiently in infrastructure to cope with demand) I’m hoping there will be a good Twitter conversation in Atlanta.
One of the hot topics this year is Multiple Myeloma, for which there are four “Super Friday” satellite symposia and over 700+ abstracts.
Earlier this year, the FDA approved Onyx’s carfilzomib (Kyprolis) and approval for Celgene’s pomalidomide (Actimid) is expected by year-end. Several other new agents are on the horizon including Millennium’s new proteasome inhibitor ixazomib/MLN9708 that Dr Sundar Jagannath discussed at the recent Chemotherapy Foundation Symposium in New York. The availability of new treatment options is certainly good news for patients.
I am looking forward to attending the ASH education session on Keeping Pace with Advances in Myeloma. Hope to see you there if you have plans to be in Atlanta next week.